Topics

Companies Related to "Early rheumatoid arthritis characterised distinct transient synovial fluid" [Most Relevant Company Matches] RSS

03:28 EST 8th December 2019 | BioPortfolio

Here are the most relevant search results for "Early rheumatoid arthritis characterised distinct transient synovial fluid" found in our extensive corporate database of over 50,000 company records.

Showing "Early rheumatoid arthritis characterised distinct transient synovial fluid" Companies 1–25 of 1,600+

Extremely Relevant

Enbrel® (etanercept)

Enbrel® (etanercept) is a TNF inhibitor approved for the following indications: moderately to severely active rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (arthritis of the spine) and psoriasis.


Chesapeake Biological Laboratories, Inc.

Chesapeake Biological Laboratories, Inc. (CBL) was founded in 1980 by William P. Tew, Ph.D., Paul Wilks, and Samuel Cross to develop practical applications for Dr. Tew's research at The Johns Hopkins University of Medicine in degenerative joint disease. Messrs. Wilks and Cross each invested $15,000 in the Company to build and equip a 400 square foot laboratory in the basement of Dr. Tew's home. ...

Relevant

CD Diagnostics, Inc.

CD Diagnostics (www.cddiagnostics.com) is developing a series of immunoassays to detect the cause of joint pain using joint fluid analysis. The assays use a small sample of a patient’s joint fluid (called synovial fluid) to measure the presence of proteins (also known as biomarkers) that are produced by the body and are specific to a particular joint ...


Plexxikon Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, is in late-stage clinical trials for the treatment of melanoma. Other clinical-stage programs include PLX5568 for the treatment of polycystic kidney disease, PLX204 for the treatment ...

International Foundation for Autoimmune Arthritis

The International Foundation for Autoimmune Arthritis (IFAA) was established in 2010 after its founder, Tiffany Westrich, was diagnosed with Rheumatoid Arthritis. She united with other autoimmune arthritis patients who were also current or former business executives and educators, creating the first global nonprofit for these diseases. IFAA is committed...

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...

Arthritis Foundation, Southern California Chapter

Established in 1948, the Arthritis Foundation is the only national voluntary organization that works on behalf of people with all forms of arthritis. The Arthritis Foundation funds research to find cures and improve care, issues up-to-date information about arthritis and its treatment, and offers exercise and support groups for those with arthritis. For more information, please call 1.800.954.2873...

SFA Therapeutics, Inc.

SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-KB mediated pathways. Chronic inflammation has been implicated in a wide range of diseases, including Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease ...

Protalex

Protalex (OTC:PRTX) is a biotechnology company developing a novel, new class of drugs for the treatment of various autoimmune disorders. The company’s lead compound, PRTX-100, is currently in development for idiopathic thrombocytopenic purpura, a rare blood clotting disorder, and rheumatoid arthritis. PRTX-100, a highly-purified form of Staphylococcal Protein A (SpA or Protein A) has been used ...

The Arthritis Foundation, Southeast Region, Georgia Office

The Arthritis Foundation (www.arthritis.org) is the leading health organization addressing the needs of the 46 million Americans, including 300,000 children, living with arthritis, the nation's most common cause of disability. The Foundation helps individuals take control of arthritis by providing public health education; pursuing public policy and legislation; supporting research and conducting e...

ModiQuest Research

Monoclonal Antibody Therapeutics and Diagnostics For Rheumatoid Arthritis & Cancer ModiQuest Group was founded in 2004 and is based in Nijmegen, The Netherlands. It consists of ModiQuest Therapeutics B.V, focused on the development of novel monoclonal antibody therapeutics and diagnostics for autoimmune and oncology targets, and ModiQuest Research, which provides technology and contract re...

Rigel Pharmaceuticals

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellu...

SFA Therapeutics

SFA Therapeutics is a bio-pharmaceutical company focused on new advancements in the treatment of inflammatory diseases, targeting NF-κB. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, lupus (SLE), inflammatory bowel disease (IBD), Crohn's Disease, psoriasis, liver disease a...

Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a personalized medicine company developing revolutionary new products and services to customize diagnosis and treatment of patients with rheumatoid arthritis, lupus and other autoimmune diseases.

Johnson and Johnson (France)

Our pharmaceuticals companies offer medicines that treat many of the world's most serious and widespread diseases. These diseases range from cancer, HIV/AIDS and bacterial infections to schizophrenia, epilepsy, rheumatoid arthritis and psoriasis. In 2007, we invested $5.3 billion in the search for new ways to treat these diseases and many others. It’s all part of our commitment to helping you an...

Cartela AB

Cartela is a biotech company dedicated to the development of innovative therapies in arthritic diseases, primarily osteoarthritis and rheumatoid arthritis. There is still no curative treatment available for arthritic diseases and current treatment options for associated chronic pain are insufficient. A new therapeutic approach is therefore highly needed.Cartela's business is based on the cell surf...

BIOTECTID GmbH

"Biotectid is specialized in the development and production of innovative in vivo diagnostics for medical imaging of chronic inflammation diseases. The main indication of which is rheumatoid arthritis (joint rheumatism). The company maintains an in-house GMP-production plant for IMP""s. The lead-product is already in clinical trials."

ENBREL

ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your d...

Merrimack Pharmaceuticals,Inc.

Merrimack Pharmaceuticals, Inc. is a privately held biotechnology company based in Cambridge, Massachusetts. We are dedicated to the discovery and development of innovative therapies for the treatment of autoimmune disease and cancer. Our goal is to provide patients and physicians with not only the best possible treatments, but to support our pharmaceuticals with the tools to enable the prescrip...

Encynova

Encynova designs and manufactures superior fluid control systems for a broad range of metering and dispensing applications. The revolutionary Travcyl™ pump design provides exceptional accuracy and control for a variety of dispensing and low-flow metering uses. The pharmaceutical, medical, and biotech industries employ these fluid systems for manufacturing, process control and automation. The ink...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

BioMedical Research Models Incorporated (BRM)

Biomedical Research Models, Inc. (BRM) is a full service Contract Research Organization. We specialize in value added studies using our propriety model systems. BRM conducts studies on the efficacy of new drugs to improve Type 1 and Type 2 diabetes, diabetic complications, cancer, rheumatoid arthritis and auto-immune disease.

AtheroGenics Incorporated

AtheroGenics is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma. AtheroGenics has cultivated a drug discovery and development capability directed toward rapidly creating and transporting small molecule therapeutics into the clini...

Chelsea Therapeutics

We are a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of a variety of human diseases. Our strategy is to develop technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Specifically, Chelsea concentrates its efforts on acquiring and developing technologi...

ARC Pharmaceuticals Inc

ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing innovative medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a...


More From BioPortfolio on "Early rheumatoid arthritis characterised distinct transient synovial fluid"

Quick Search

Corporate Database Quicklinks